N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

DISEASE CHARACTERISTICS: * Diagnosis of neuroblastoma as evidenced by one of the following: * Histological confirmation * Demonstrates clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites * High-risk refractory or residual disease * Poorly responding disease, meeting 1 of the following criteria: * Stable disease or partial response after at least 12 weeks of induction therapy * Bone marrow containing greater than 100 tumor cells per 100,000 normal cells after 12 weeks of induction therapy * Progressive disease during or after therapy * At least 1 prior positive iodine I 131 metaiodobenzylguanidine (131 I-MIBG) scan since diagnosis and meets disease status criteria PATIENT CHARACTERISTICS: Age: * 1 to 21 (1 to 20 at diagnosis) Performance status: * ECOG 0-2 Life expectancy: * At least 2 months Hematopoietic: * Absolute neutrophil count at least 500/mm\^3 * Platelet count at least 20,000/mm\^3 (transfusion allowed) * Hemoglobin at least 8 g/dL (transfusion allowed) Hepatic: * Bilirubin normal * AST/ALT no greater than 3 times normal * No active hepatitis (for HIV-positive patients only) Renal: * Glomerular filtration rate or creatinine clearance at least 60 mL/min * Creatinine less than 1.5 times normal for age Cardiovascular: * Ejection fraction at least 55% OR * Fractional shortening at least 30% Pulmonary: * No dyspnea at rest or exercise intolerance * No requirement for supplemental oxygen * No active pneumonia (for HIV-positive patients only) Other: * No disease of any major organ system that would preclude study participation * No other active health problems (for HIV-positive patients only) * No active infections requiring intravenous antivirals, antibiotics, or antifungals * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 3 weeks since prior biologic therapy and recovered Chemotherapy: * At least 3 weeks since prior chemotherapy and recovered * No more than 100 mg/m\^2 total dose of prior melphalan Endocrine therapy: * Not specified Radiotherapy: * No prior total body, whole abdominal, or whole liver irradiation * No prior therapy with 131 I-MIBG * At least 2 weeks since prior radiotherapy (6 months for prior radiotherapy to craniospinal or whole lung fields or greater than 50% of bone marrow space) and recovered Surgery: * Prior surgical resection allowed * Recovered from prior surgery Other: * No prior myeloablative therapy * Prior submyeloablative therapy with peripheral blood stem cell support allowed * No concurrent antiretrovirals for HIV-positive patients * Concurrent prolonged antifungal allowed if culture and biopsy negative in suspected residual radiographic lesions * No medications that may preclude uptake of 131 I-MIBG for 1 week prior and 2 weeks after administration of study drugs * No concurrent hemodialysis